Neal Shore, MD, FACS, Carolina Urologic Research Center, Myrtle Beach, SC, provides an analysis of the Phase III PROpel trial (NCT03732820) of olaparib and abiraterone in first-line metastatic castration-resistant prostate cancer (mCRPC). The gene-specific analysis unveiled that BRCA2, ATM, and CDK12 mutations were most prevalent, with a notable clinical benefit observed in patients with these mutations. Dr Shore additionally discusses the nuances of individual gene mutations, emphasizing the significant treatment benefit seen in BRCA-mutated patients. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть